Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Starton Therapeutics receives first clinical regulatory authorization for its STAR-LLD program

% of readers think this story is Fact. Add your two cents.


Starton Therapeutics Inc announced it has received its first Clinical Trial Authorization in the Netherlands to start a Phase 1 study on its STAR-LLD continuous delivery lenalidomide.

STAR-LLD is a continuous delivery lenalidomide in development to expand the standard of care for the most common blood cancers, multiple myeloma and chronic lymphocytic leukemia (CLL).

The study will evaluate the 24-hour bioavailability, safety, tolerability and pharmacokinetics in human subjects compared to oral lenalidomide.

READ: Starton Therapeutics advances transdermal lenalidomide STAR-LLD program following successful skin permeation studies

Phase 1 is an open-label, crossover design used to confirm the plasma concentrations of STAR-LLD versus oral lenalidomide that will be further evaluated in a randomized Phase 1b study in patients with multiple myeloma, Starton told investors.

The firm’s CEO Pedro Lichtinger called the authorization an “important milestone” for the Paramus, New Jersey-based company, highlighting it as Starton’s first clinical regulatory authorization for the STAR-LLD program.

The study provides comparative rapid confirmation of blood levels so that Starton can move in to the clinic in multiple myeloma, chief medical officer Jamie Oliver told shareholders.

“We have designed the most efficient study to meet regulatory requirements, assess safety, and bring STAR-LLD to a patient population as soon as possible,” Oliver added.

Starton said it plans to submit additional regulatory applications in other countries as part of its development approach for STAR-LLD.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Story by ProactiveInvestors



Source: https://www.proactiveinvestors.com/companies/news/970760/starton-therapeutics-receives-first-clinical-regulatory-authorization-for-its-star-lld-program-970760.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.